Targeted therapies that inhibit JAK-STAT signaling, such as JAK2 inhibitors (e.g., ruxolitinib and fedratinib), have shown efficacy in adult hematologic malignancies and are being explored in pediatric settings. The gene discussed is SOAT1; the disease is hematologic disorder.